The global generic drug manufacturing market was valued at USD 476.02 Billion in 2025 and is expected to grow at a CAGR of 6.20%, reaching USD 868.70 Billion by 2035. The market growth is driven by increasing demand for cost-effective medications and the expiration of patents for several branded drugs. Expansion of healthcare access in emerging economies and growing prevalence of chronic diseases are supporting market growth. Advances in manufacturing technologies and regulatory frameworks facilitating faster approvals are also expected to boost market value during the forecast period.
Base Year
Historical Period
Forecast Period
According to the World Health Organization (WHO), over 1 in 3 people are affected by neurological conditions, the leading cause of illness and disability worldwide. This rising prevalence is driving growth of the generic drug manufacturing.
The market is experiencing robust growth driven by rising demand for affordable therapies, increasing prevalence of chronic conditions, and expanding access to healthcare across emerging and developed regions.
Strategic investments, advanced manufacturing capabilities, and a strong emphasis on research and development by leading market participants are enhancing operational efficiency and innovation, thereby significantly contributing to the overall growth of the global generic drug market.
Compound Annual Growth Rate
6.2%
Value in USD Billion
2026-2035
*this image is indicative*
Generic drug manufacturing involves the large-scale production of cost-effective pharmaceutical alternatives after original patents expire, focusing on quality, safety, and regulatory compliance. The market is witnessing significant expansion, driven by rising healthcare demand, patent expirations, and cost-conscious treatment approaches. The market is poised to grow at a CAGR of 6.20% during the forecast period of 2026-2035, reflecting increasing adoption of generic medicines worldwide, technological advancements in production, and supportive government initiatives to enhance accessibility and affordability of essential drugs.
Rising Cancer Incidence to Elevate the Market Growth
The increasing prevalence of cancer is a significant growth driver in the market. According to the World Health Organization (WHO), over 35 million new cancer cases are projected by 2050, representing a 77% increase from approximately 20 million cases in 2022. This surge is attributed to population aging, population growth, and changes in exposure to various risk factors linked to socioeconomic development. As the global cancer burden escalates, demand for cost-effective generic oncology medications is expected to rise, supporting sustained growth in the market.
The market is experiencing multiple key trends, including increasing global regulatory collaboration and the growing adoption of generic and biosimilar medicines.
Global Regulatory Collaboration to Boost the Market Landscape
The market is witnessing significant growth, driven by enhanced international regulatory collaboration and scientific alignment. In June 2024, the Generic Drug Cluster, led by the U.S. FDA, celebrated its third anniversary, highlighting its role as a strategic forum where leading regulatory agencies share knowledge, discuss policy developments, and align on best practices for generic drug development. By fostering harmonization and strengthening regulatory standards globally, initiatives like these are enabling faster approvals, improving drug quality, and expanding market access. This trend is expected to continue boosting the overall market growth in the coming years.
Rising Adoption of Generic and Biosimilar Medicines Likely to Boost Market Growth
The increasing adoption of cost-effective alternatives to brand-name drugs is a significant driver propelling market growth. For instance, in September 2025, the Association for Accessible Medicines and the Biosimilars Council highlighted that generic and biosimilar medicines generated USD 467 billion in savings for the U.S. healthcare system in 2024, covering 90% of all prescriptions while representing only 12% of total drug spending. Companies across the biosimilars sector continue to expand patient access and therapy options. This growing reliance on generics and biosimilars is expected to drive sustained market growth in the coming years.
Cardiovascular Segment is Expected to Lead the Market by Therapeutic Area
The market includes various therapeutic areas such as cardiovascular, central nervous system (CNS), oncology, anti-infectives, gastrointestinal, musculoskeletal, respiratory, endocrine/diabetes, and others. Among these, the cardiovascular segment is expected to lead the market due to the high prevalence of cardiovascular diseases worldwide. According to the World Heart Federation, more than half a billion people globally are affected by cardiovascular conditions, accounting for 20.5 million deaths in 2021 alone, representing nearly a third of all deaths globally. This significant disease burden drives the demand for effective treatments in this segment, making it the dominant area in the market.
The market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Among these, North America is expected to lead the market due to regulatory support, robust pharmaceutical infrastructure, and initiatives promoting domestic manufacturing. Notably, the U.S. Food and Drug Administration (FDA) announced a new Abbreviated New Drug Application (ANDA) prioritization pilot to incentivize U.S.-based testing and production in October 2025. This program aims to strengthen the domestic supply chain, enhance drug safety, and accelerate access to high-quality, U.S.-made generic medicines.
The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Teva Pharmaceutical Industries is a leading player in the market, offering a wide range of Teva Generic Medicines. The company focuses on delivering high-quality, safe, and effective medications that enhance healthcare affordability and accessibility. Teva is actively involved in developing complex generics and biosimilars, leveraging advanced scientific expertise and a robust global supply chain to provide innovative, cost-effective solutions for patients worldwide.
Sun Pharmaceuticals, India’s leading pharmaceutical company, is a prominent player in the generic drug manufacturing market. With over 40 manufacturing facilities and a portfolio exceeding 2,000 products, the company delivers high-quality medicines across more than 100 countries. Sun Pharma’s offerings span multiple therapeutic areas, including dermatology, neuropsychiatry, oncology, cardiovascular, and anti-infectives, supporting patient care and global access to affordable generic medicines.
Viatris is a global pharmaceutical company actively involved in the market, offering a broad portfolio of generic, complex generic, and branded generic medicines. Their products, such as Wixela Inhub and glatiramer acetate injection, provide the same clinical benefits as brand-name counterparts while enhancing patient access and affordability. Viatris ensures high-quality manufacturing standards, adhering to global Good Manufacturing Practices (GMP) and regulatory inspections, supporting safe, effective, and accessible medications worldwide.
Cipla Ltd. is a leading pharmaceutical company actively engaged in the market. The company offers a diverse portfolio of generic medications, including analgesics, antipyretics, antiemetics, antacids, anti-allergens, anti-asthmatics, and various antibiotics. Cipla’s products, such as paracetamol-domperidone combinations, cetirizine-based formulations, and broad-spectrum antibiotics like azithromycin and amoxicillin-clavulanate, demonstrate its strong presence and commitment to providing affordable, high-quality generics to meet healthcare demands globally.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Novartis AG, Fresenius Kabi, Lupin Group, Zydus Lifesciences, Gilead Pharma, and Glenmark.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Manufacturing Type
Market Breakup by Drug Type
Market Breakup by Route of Administartion
Market Breakup by Therapeutic Area
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region
Upto 15% Off
USD
$5499 $4949
$3299 $2969
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Manufacturing Type |
|
| Breakup by Drug Type |
|
| Breakup by Route of Administration |
|
| Breakup by Therapeutic Area |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share